BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Levy, J. H., Koster, A., & Quinones, Q. J. (2018). Antifibrinolytic Therapy and Perioperative Considerations. Anesthesiology, 128(3), 657–670. Added by: Dr. Enrique Feoli (27/10/2023, 12:36) Last edited by: Dr. Enrique Feoli (27/10/2023, 12:39) |
 |
| Resource type: Journal Article DOI: 10.1097/ALN.0000000000001997 ID no. (ISBN etc.): 0003-3022 BibTeX citation key: Levy2018 View all bibliographic details  |
Categories: BioAcyl Corp Subcategories: Heridas quirúrgicas Creators: Koster, Levy, Quinones Collection: Anesthesiology |
Views: 3/275
|
| Abstract |
|
{Fibrinolysis is a physiologic component of hemostasis that functions to limit clot formation. However, after trauma or surgery, excessive fibrinolysis may contribute to coagulopathy, bleeding, and inflammatory responses. Antifibrinolytic agents are increasingly used to reduce bleeding, allogeneic blood administration, and adverse clinical outcomes. Tranexamic acid is the agent most extensively studied and used in most countries. This review will explore the role of fibrinolysis as a pathologic mechanism, review the different pharmacologic agents used to inhibit fibrinolysis, and focus on the role of tranexamic acid as a therapeutic agent to reduce bleeding in patients after surgery and trauma.}
|